Contrary to what has been shown in patients with diabetes and advanced colorectal or airway cancers, exposure to DPP4 inhibitors did not lead to statistically significant improvement in PFS in patients with advanced-stage prostate cancer. Here, DPP4 is linked to prostate carcinoma.